Fludarabine induces differential expression of proteins in human leukemia and lymphoma cells

Nucleosides, Nucleotides and Nucleic Acids

Volumn 27, Issue 6-7, 2008, Pages 634-640

  Henrich, S ^a   Gez, S ^a   Crossett, B ^a   Mulligan, S P ^a   Christopherson, R I ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Apoptosis; CD antigens; Fludarabine; Mechanism; p53; Phosphorylation

Indexed keywords

B7 ANTIGEN; CD20 ANTIGEN; CD86 ANTIGEN; FLUDARABINE; INTERCELLULAR ADHESION MOLECULE 1; PROTEIN P53;

CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAJI CELL;

ANIMALS; ANTIBODIES; ANTIGENS, CD; APOPTOSIS; CATTLE; CELL LINE, TUMOR; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA; LYMPHOMA; TUMOR SUPPRESSOR PROTEIN P53; VIDARABINE;

EID: 46749090411     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770802142287     Document Type: Conference Paper

References (11)

1. Lamanna, N.; Weiss, M. Purine analogs in leukemia. Adv. Pharmacol. 2004, 51, 107-125.
2. Pettitt, A. R. Mechanism of action of purine analogues in chronic lymphocytic leukaemia. Br. J. Haematol. 2003, 121, 692-702.
3. Elter, T.; Hallek, M.; Engert, A. Fludarabine in chronic lymphocytic leukaemia. Expert Opin. Pharmacother. 2006, 7, 1641-1651.
4. Pettitt, A.R.; Clarke, A.R.; Cawley, J.C.; Griffiths, S.D. Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms. Br. J. Haematol. 1999, 105, 986-988.
5. Henrich, S.; Cordwell, S.J.; Crossett, B.; Baker, M.S.; Christopherson, R.I. The nuclear proteome and DNA-binding fraction of human Raji lymphoma cells, Biochim. Biophys. Acta 2007, 1774, 413-432.
6. Belov L.; Huang, P.; Barber, N.; Mulligan, S.P.; Christopherson, R.I. Identification of repertoires of surface antigens on leukemias using an antibody microarray. Proteomics 2003, 3, 2147-2154.
7. Toledo, F.; Wahl, G.M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas, Nature 2006; 6:910-923.
8. Roos, W. P.; Kaina, B. DNA damage-induced cell death by apoptosis. Trends Mol. Med. 2006, 12, 440-450.
9. Sadji-Ouatas, Z.; Lasfer, M.; Julien, S.; Feldmann, G.; Reyl-Desmars, F. Doxorubicin and octreotide induce a 40 kDa breakdown product of p53 in human hepatoma and tumoral colon cell lines. Biochem. J. 2002, 364, 881-885.
10. Okorokov, A.L.; Milner, J. Proteolytic cleavage of p53: a model for the activation of p53 in response to DNA damage. Oncol. Res. 1997, 9, 267-273.
11. Byrd, J.C.; Rai, K.; Peterson, B.L.; Appelbaum, F.R.; Morrison, V.A.; Kolitz, J.E.; Shepherd, L.; Hines, J.D.; Schiffer, C.A.; Larson, R.A. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005, 105, 49-53.